Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol as a Modifier of 6-MP Metabolism in Pediatric ALL
NCT02046694Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2014
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allopurinol in acute lymphoblastic leukemia (ALL), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Absolute neutrophil count at 8 weeks. Started Jan 2014; status: completed.
02
Drugs
allopurinol
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02046694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02046694.